Clinical trial Recruiting at 1 site Interventional Ages 50 to 90 Men only

Effects of mTOR Inhibition on Muscle Health in Older Adults

Official title: Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle.

Run by University of Nottingham · NCT05414292 · Data updated 2026-11-12

This study is testing if a medication called Rapamune can help older adults with muscle loss get stronger when they do resistance exercises.

More Muscle Atrophy trials

Quick facts

Study typeInterventional
Ages50 Years to 90 Years
SexMen only
Enrollment16 (estimated)
SponsorUniversity of Nottingham
Academic / other
Locations1 site (Derby)
StatusRecruiting
StartedAugust 6, 2021
Main results expectedMay 1, 2027
Study endsMay 1, 2027
Registry record updatedApril 10, 2025
Trial IDNCT05414292 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are older adults who are physically able to participate in resistance exercise training and are experiencing muscle atrophy or sarcopenia.

Probably not a fit

Patients with significant cardiovascular, respiratory, or metabolic diseases, or those with a BMI outside the specified range, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of inhibiting the mechanistic target of rapamycin (mTOR) on muscle health in older adults experiencing muscle atrophy and age-related sarcopenia. Participants will undergo unilateral resistance exercise training while receiving Rapamune (sirolimus) to assess its impact on muscle protein synthesis and overall muscle function. The study aims to explore whether mTOR inhibition can enhance muscle responses to exercise in individuals who may not be able to engage in regular physical activity. By understanding the role of mTOR in muscle maintenance, the research seeks to identify potential therapeutic strategies for combating age-related muscle loss.

Why it matters

Potential benefit: If successful, this study could provide a new pharmacological approach to improve muscle mass and function in older adults, enhancing their quality of life and independence.

How similar studies have gone: While the approach of mTOR inhibition has shown promise in animal studies, this specific application in humans is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study
* Participant is physically able to complete the resistance exercise training programme

Exclusion Criteria:

* • A BMI \<18 or \>35 kg/m2

  * Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP \> 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent stroke
  * Any metabolic disease
  * Clotting dysfunction
  * A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)
  * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (this must remain for ALL UoN FMHS UREC approved studies)
  * Contraindications to MRI scanning including claustrophobia, pacemaker, metal implants etc. which will be assessed through an MRI safety screening questionnaire.
  * Contraindications to the use of Rapamycin e.g. those due scheduled vaccinations (as rapamycin can reduce the efficacy of vaccines).

Where it's running

  • University of Nottingham School of Medicine
    Derby, United Kingdom
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.